[en] OBJECTIVE: A 'case scenario' study on clinical decisions in progressing Parkinson's disease (PD) was developed to complement scientific evidence with the collective judgment of a panel of experts. METHODS: The opinions of 9 experts in movement disorders on the appropriateness of 9 common pharmacological treatments for 33 hypothetical patient profiles were compared to those of 14 general neurologists. Before rating the case scenarios, all participants received a document integrating European and US guidelines for the treatment of patients with advanced PD. Case scenarios showing disagreement or with inconsistencies in appropriateness ratings were discussed at a feedback meeting. A tool for interactive discussion on the clinical case scenarios included was developed based on the outcome of the study. RESULTS: Current guidelines are often insufficient to adequately guide the management of patients with progressing PD. The case scenario study did not reveal major differences in opinions between experts in movement disorders and general neurologists about the appropriateness of certain drug choices for specific case scenarios. However in about 1 out of 5 treatment decisions where experts stated appropriateness or inappropriateness, the general neurologists panel had no or dispersed opinions. CONCLUSIONS: This study reveals more uncertainty about treatment of advanced PD in general neurologists compared with experts in movement disorders and underlines the need for additional support for guiding treatment decisions in clinical practice.
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448-458.
Bonuccelli U, Pavese N. Dopamine agonists in the treatment of Parkinson's disease. Expert Rev Neurother. 2006;6:81-89.
Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K. et al. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/ entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol. 2005;53:197-202.
Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL. et al. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology. 1989;39:7-10.
Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998;64:573-576. (Pubitemid 28204140)
Contin M, Riva R, Martinelli P, Cortelli P, Albani F. et al. Concentration-effect relationship of levodopa- benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease. Clin Neuropharmacol. 1999;22:351-355.
Durif F, Debilly B, Galitzky M, Morand D, Viallet F. et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology. 2004;62:381-388.
Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908-1910. (Pubitemid 29260911)
Golbe LI, Lieberman AN, Muenter MD, Ahlskog JE, Gopinathan G. et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol. 1988;11:45-55. (Pubitemid 18039433)
Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. Mov Disord. 2005;20:1397-1404.
Hardoff R, Sula M, Tamir A, Soil A, Front A. et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord. 2001;16:1041-1047. (Pubitemid 36041216)
Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A. et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol. 2006b;13:1186-1202.
Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A. et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol. 2006a;13: 1170-1185.
Jorga K, Fotteler B, Schmitt M, Nielsen T, Zürcher G. et al. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur Neurol. 1997;38:59-67.
Kahn KL, Kosecoff J, Chassin MR, Flynn MF, Fink A. et al. Measuring the clinical appropriateness of the use of a procedure. Can we do it? Med Care. 1988;26:415-422.
Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M. et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord. 2005;20:151-157. (Pubitemid 40361117)
Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/ levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology. 1999;53:1012-1019.
Kurth MC, Tetrud JW, Tanner CM, Irwin I, Stebbins GT. et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology. 1993;43:1698-1703.
Lees AJ, Shaw KM, Kohout LJ, Stern GM, Elsworth JD. et al. Deprenyl in Parkinson's disease. Lancet. 1977;2:791-795.
Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci. 2005;17:214-220. (Pubitemid 41350609)
Lieberman AN, Gopinathan G, Neophytides A, Foo SH. Deprenyl versus placebo in Parkinson disease: a double-blind study. N Y State J Med. 1987;87:646-649. (Pubitemid 18008990)
Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson J L. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med. 1984;310: 483-488.
Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B. et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64:216-223.
Olanow CW, Obeso JA, Stocchi F. Continuous dopamine- receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677-687. (Pubitemid 44081890)
Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G. et al. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983-995. (Pubitemid 44044780)
Parkinson Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241-248.
Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM. et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 2002; 77:1280-1286. (Pubitemid 35403801)
Rascol O, Brooks D J, Melamed E, Oertel W, Poewe W. et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947-954. (Pubitemid 41071428)
Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol. 1996;19:283-296.
Santens P, Maertens De Noordhout A, For The Belgian EODWO Study Group Detection of motor and non- motor symptoms of end-of dose wearing-off in Parkinson's disease using a dedicated questionnaire: a Belgian multicenter survey. Acta Neurol Belg. 2006;106:137-141. (Pubitemid 44613874)
Snow BJ; Macdonald L, Mc Auley D, Wallis W The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo- controlled study. Clin Neuropharmacol. 2000;23: 82-85. (Pubitemid 30212217)
Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol. 2005;62:905-910. (Pubitemid 40973452)
Van Camp G, Flamez A, Cosyns B, Goldstein J,. Perdaens C. et al. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology. 2003;61:859-861. (Pubitemid 37174494)
Verhagen Metman L, Del Dotto P, Van Den Munckhof P, Fang J, Mouradian MM. et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 1998;50:1323-1326. (Pubitemid 28240346)
Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH. et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63:969-973. (Pubitemid 44036299)
Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M. et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology. 2002;59:408-413. (Pubitemid 34857934)
